Overview
Survodutide is a breakthrough dual GLP-1 and Glucagon receptor agonist engineered for powerful metabolic weight loss and liver disease reversal.
What problem it targets: It targets severe obesity, metabolic dysfunction-associated steatohepatitis (MASH / NASH), advanced liver fibrosis, and stalled fat loss.
What It Does
• Dual-action metabolic synergy: GLP-1 activation suppresses appetite and reduces caloric intake, while glucagon activation fires up energy expenditure and liver fat oxidation.
• Reverses metabolic liver fibrosis: Directly targets hepatic cells to resolve liver inflammation, clear accumulated triglycerides, and reverse early fibrotic scarring.
• Keeps metabolic burn elevated during dieting: Prevents the natural dip in basal metabolic rate that usually occurs during substantial weight loss.
• Realistic expectations: Administered as a once-weekly subcutaneous injection. Clinical trials show exceptional liver clearance alongside ~19% body weight reduction in obese adults over 48 weeks.
Reconstitution
| Vial size | BAC water / Solvent | Concentration |
|---|---|---|
| 10 mg | + 2 mL | 5 mg/mL |
Protocol
| Phase (4 | Frequency | Dose | Units (2.5 mg/mL) | Notes |
|---|---|---|---|---|
| Weeks 1–4 | Once | 0.6 mg | 24u | Intro phase, adapt to dual GLP-1 + glucagon stimulation. weekly |
| Weeks 5–8 | Once | 1.2–2.4 | 48–96u | Step up only if well tolerated. |
| weekly | mg | |||
| Weeks 9–16 | Once | 3.6–4.8 | (switch to 5 mg/mL: | Target range. 4.8 mg/week is the trial target. |
| weekly | mg | 72–96u) | ||
| Maintenance | Once | 4.8–6 | – | 4.8 mg = Phase 2 target (NCT04667377); 6 mg = Phase 3 SYNCHRONIZE max. Do not exceed 6 mg, |
| weekly | mg | higher figures are unverified community claims. Cycle: titrate over 14–20 weeks; the glucagon component makes nausea more likely than pure GLP-1, so go slowly. Timing: same day each week, any time. Note: generally harsher on GI than mazdutide, don’t rush the ladder. Women: Women lose more than men at the same dose but report more GI (start lower). In PCOS they improve cycles, lower free testosterone and raise ovulation; a real unplanned-pregnancy risk. Stop before conceiving. Men: In men, excess fat lowers testosterone; GLP-1 raises total testosterone, SHBG and gonadotropins as weight drops, and improves sperm and erectile function; and preserves fertility, unlike TRT (which suppresses sperm). |
Handling & Stacking
- Freeze-dried: -4°F.
- Reconstituted: 36–46°F.
- Best used within ~3–4 weeks, kept cold (structure-based estimate, no published data); that is close to the 28- day sterility limit, so use whichever comes first.
Safety & Patient Education
- Fasting glucose / HbA1c (baseline + periodic) Liver enzymes (often the point of therapy, track ALT/AST) Lipase if pancreatitis suspected; renal function with GI losses Resting heart rate / blood pressure Out of range?
- Rising glucose/HbA1c = sugar creeping up; rising ALT/AST = liver stress (often the point of therapy, track the trend).
